Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
These days of sub-penny changes will soon be long forgotten after earnings are released.
Due diligence means research based on facts and backed up with links. It does not mean throwing out wild, baseless misleading opinions.
That would put the pops at .30 you mean.
The CEO has an impressive resume and we have yet to see how the stock performs under his lead, he is digging out from a premature SEC application. Given the revenues, upcoming catalysts and the low share price, it is fairly low risk at this time.
Your due diligence we thank you for.
Ditto, earnings announcement first any day now, audit may take a bit longer. I also have a feeling that POTN will have a larger company, probably a producer of CBD, take a stake and become the CBD provider in return for access to the distribution channels. Tilray would be an example. All just my opinion, of course, but I can see little downside at this time with price to revenues equal to 2.
From the last 6 months of press releases I see hints about revenues including "record sales, 400 new orders, surge in interstate commerce and exponential growth". From this, I expect over 6 million in revs for the 4th Q and over 24 million for the year, with the possibility of an upside surprise bringing 2018 up to 26 million with projected acceleration in revenues. We also know that SEC registration and uplist will occur as soon as the full year audit is complete, bringing in bigger new investors and higher confidence levels.
I think they are maturing to a company that reports quarterly and have been in the process switching over to a new auditor. I would rather wait and avoid any more retractions. Could be that blockchain is now implemented for more accuracy too.
I am looking for release of 2018 revenues to ignite this stock- which could be any day next week. Hoping we don't have to wait until Feb.
POTN will catch up with the other high potential CBD and MJ companies that are already fairly valued this year IMO, and I am making a watch list for diversification in the future.
Similarly, I think CBD (rather than MJ) is "the next big thing" and 2019 is the year of CBD. In the late 90's I made a killing on Netflix, AOL and EBAY. I haven't seen a similar situation until now, and my expertise is in developing botanicals and food components as supplements to treat illnesses.
And then there is the new CBD cotton candy and coffee...
I agree that POTN has the most potential for share price elevation at this time. There are many good companies out there that have already overrun their current earnings. Once POTN shows that there is no longer risk and instability by registration with the SEC, uplisting and reporting growing revs, the sky is the limit in the short term.
Nice green day for the cannabis sector, I cannot remember the last time my whole screen was green.
Once we finally get SEC registered and uplisted, at least we will get some analyst coverage and we will be out of this black hole.
No reason to suspect a delay, today is the date 4th Q and full year were released last year. I would expect that they need time to process and include December's large number of orders in earnings for the year. A delay might just as likely indicate a large number orders to process in accounts receivable.
Yep, $1000 today in POTN will be worth $10,000 in a few months IMO, why I am buying more here.
There is no dilution. Please post a link if you make extreme claims.
IMO earnings will not be delayed because of the timing of this court date (it's a non-event).
Hoping for this week, it was Jan 24 last yer.
I disagree, I run a preclinical lab that studies botanicals and food components that can be used to treat diseases. A little sugar to make all of the other very healthy ingredients palatable won't hurt you. Niacinamide is a compound we study that has been found to have many beneficial effects, for example, extending length of life and improving mitochondrial function. This is a healthy combination of ingredients.
POTN is already expanding into global markets- Europe and South Africa, two of the four growing most rapidly. Don't know about the other two, Asia and South America.
I am starting so see more articles on CNBC and Bloomberg by analysts in agreement that CBD will be more profitable- time will tell.
CBD will be much bigger than THC IMO. CBD treats the major most prevalent medical conditions, pain, insomnia, and anxiety without side effects or getting too buzzed to go to work. Additionally, CBD has potential- clinical trials still underway, to treat cancer, obesity, diabetes and more inflammatory diseases. THC is necessary for appetite problems as in cachexia, chemotherapy or AIDS and possibly glaucoma.
See the post by Potnic about 10 posts ago.
They withdrew their application to he SEC twice, once because the accounting firm they were using lost accreditation (nothing to do with POTN) and once because they didn't have 2 full years of audited earnings- which they have now. Nothing will hold POTN back when they register with the SEC (any day now when the govt reopens) and report 2018 earnings.
CBD is being studied by multiple labs for anti-cancer activity. Please know that turmeric has very potent anti-cancer activity and I have tested it in my laboratory of my previous cancer pharmaceutical company, so I strongly recommend CBD with turmeric products in the DiamondCBD medical product line.
Nationally legal CBD will sweep across the USA at an incredible rate in 2019, even among the elderly (who need it the most). The companies that have the infrastructure to get great products in front of the upcoming wave of buyers will see an exponential increase in revenues. POTN Prescription not needed, walk to the vending machine or order online.
POTN has been operating carefully within the regulations of the FDA, as demonstrated by their statements in press releases. The FDA allows food components and natural compounds to be sold in supplements as long as there is no claim regarding efficacy for treatment that hasn't been proven in clinical trials. That said, the govt clinical trial to test addictive potential of CBD has been completed and published, and data shows no abuse potential. Trials are in progress to test efficacy for a number of conditions. The FDA urgently needs to update their classification and regulations and the DEA needs to remove it from schedule 4.
Jan 24, 2018 revenues were reported for 4th Q and full year 2017. Tuesday Jan 22 at the open this year? Definite possibility.
And if he waits a month his shares are worth 10-fold more, which to him is what- 50 million more? So he would sell now?
Vacarro's preferred shares are locked up and he stands to make hundreds of millions more than us when POTN gets to dollars, why on earth would he be selling now? Makes no sense, he already got $25 million last Feb.
Thats what I have been thinking, audit was already done except for December so it should be out shortly, as in next week.
Wouldn't want to be short POTN next week.
The news is coming, next week (based on Jan 2018 earnings date) or as late as Feb. 11. In my experience TD Ameritrade is not always accurate with earnings dates. Read the last 6 months of press releases if you have any doubts that the revs will be jumping higher.
https://www.potnetworkholding.com/media/press
No others as undervalued with as high of levels of current revenues and potential for revenue acceleration. Go back and read the past 6 months of press releases by POTN.
At least we know that stellar earnings are coming soon, probably next week based on last year's reporting of 4th Q and full year revenues.
Coming soon, probably next week based on last year's earnings announcement.
POTN fair value is .30 to .50 based on LAST years lowest revenue estimate (22 million). When 4th quarter is reported, it won't take long to get to to a much higher forward PE-based fair value IMO.
My best case scenario is revenue bump of 50% between 3rd and 4th quarters to 9 million, bringing 2018 to 27 million. That said, I like your numbers better but that is very high.